{"id":424476,"date":"2021-01-29T07:08:24","date_gmt":"2021-01-29T12:08:24","guid":{"rendered":"http:\/\/www.marketnewsdesk.com\/?p=424476"},"modified":"2021-01-29T07:08:24","modified_gmt":"2021-01-29T12:08:24","slug":"oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\/","title":{"rendered":"OncXerna Therapeutics Appoints Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"justify\">WALTHAM, Mass., Jan.  29, 2021  (GLOBE NEWSWIRE) &#8212; OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-based biomarker platform to potentially predict patient responses to its first-in-class targeted oncology therapies, today announced the appointment of Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs.<\/p>\n<p align=\"justify\">\u201cI am thrilled to reunite with Colleen and have her join our team given her deep expertise in oncology drug development,\u201d said Laura Benjamin, Ph.D., President and Chief Executive Officer at OncXerna Therapeutics. \u201cHer track record of success in developing and executing clinical development and regulatory strategies is impressive. This track record will be critical as we prepare to advance our navicixizumab and bavituximab programs towards registration trials using our unique RNA-based biomarker approach, which has the potential to bring precision medicine to more cancer patients in need of better treatments.\u201d<\/p>\n<p align=\"justify\">Prior to joining OncXerna, Ms. Mockbee served as Partner Therapeutics, Inc.\u2019s Chief Development Officer and Head of Regulatory and Quality. Previously, Ms. Mockbee established her distinguished career at Eli Lilly and Company, where she spent 20 years in oncology drug development and held leadership roles in global regulatory and health outcomes. As the Verzenio\u2122 (abemaciclib) global product development leader at Eli Lilly, she combined innovation with speed to create and execute a development strategy that led to Verzenio\u2019s approval and launch for metastatic breast cancer and the first positive Phase 3 study (monarchE) for a CDK 4\/6 inhibitor in early breast cancer. Ms. Mockbee received Bachelor of Science degrees in Chemistry and Pharmacy from Butler University and an MBA from Purdue\u2019s Krannert School of Business in 2016.<\/p>\n<p align=\"justify\">\u201cThe opportunity to integrate OncXerna\u2019s novel biomarker strategy with the development of promising new treatments is very exciting,\u201d said Ms. Mockbee. \u201cI am honored to join the excellent leadership team at OncXerna and support their mission to advance precision medicine for cancer patients.\u201d<\/p>\n<p align=\"justify\">\n        <strong>About OncXerna Therapeutics <\/strong>\n      <\/p>\n<p align=\"justify\">OncXerna is aiming to deliver next-generation precision medicine for a larger group of cancer patients by leveraging the company\u2019s deep understanding of how to prospectively identify patients based on the dominant, RNA-based biology of their tumor microenvironments. This allows OncXerna to pair those patients with OncXerna\u2019s clinical-stage therapies and known mechanism of action that directly address these biologies, to dramatically improve patient outcomes. For more information on OncXerna, please visit <a href=\"https:\/\/www.globenewswire.com\/Tracker?data=WtHczsIhP4Zl19mRIAtYezrRIIQgPUl-mNF_FD6_x269BFYKEOj896hFT64zKzCrwb_vF6xCUAlgTgDkGPx9wg==\" rel=\"nofollow noopener noreferrer\" target=\"_blank\">oncxerna.com<\/a><\/p>\n<p align=\"justify\">\n        <strong>About OncXerna\u2019s RNA-based Biomarker Platform<\/strong>\n      <\/p>\n<p align=\"justify\">Existing precision medicines target only approximately 10% of cancers\u2014those with gene mutations or oncogenic drivers for a small number of genes. Using its proprietary biomarker platform, OncXerna is leveraging the company\u2019s deep understanding of tumor biology at the RNA level to identify the dominant biology underlying a patient\u2019s cancer. OncXerna\u2019s first biomarker panel is specific to the tumor microenvironment (TME Panel-1). Initial results from TME Panel-1 reveal 4 different dominant biologies, demonstrating the presence of specific patient subgroups and their predictive value in responding to treatment. OncXerna is further optimizing the biomarker platform\u2019s tumor microenvironment panel through multiple research collaborations, including a collaboration with Moffitt Cancer Center.<\/p>\n<p align=\"justify\">\n        <strong>About Navicixizumab<\/strong>\n      <\/p>\n<p align=\"justify\">Navicixizumab is an investigational anti-DLL4\/VEGF bispecific antibody that has demonstrated antitumor activity in patients who have progressed on Avastin\u00ae (bevacizumab) in a Phase 1a\/b clinical trial. The U.S. Food and Drug Administration granted Fast Track designation to navicixizumab for the treatment of high-grade ovarian, primary peritoneal, or fallopian tube cancer in patients who have received at least three prior therapies and\/or prior treatment with Avastin. OncXerna is targeting patients whose dominant tumor biology is driven by angiogenesis with a focus beyond VEGF to include broader anti-angiogenic pathways. Navicixizumab is an investigational agent that has not been licensed or approved anywhere globally, and it has not been demonstrated to be safe or effective for any use, including for the treatment of advanced ovarian cancer.<\/p>\n<p align=\"justify\">\n        <strong>About Bavituximab<\/strong>\n      <\/p>\n<p align=\"justify\">Bavituximab is an investigational antibody that reverses immune suppression by inhibiting phosphatidylserine (PS) signaling and is currently in Phase 2 clinical trials to treat a specific subset of patients with advanced gastric cancer to improve their response to anti-PD-1 treatment. The mechanism of action of bavituximab is to block tumor immune suppression signaling from PS to multiple immune cell receptor families (e.g., TIMs and TAMs). The dominant biology targeted by bavituximab may be relevant for patients with many types of solid tumors whose immune systems are too suppressed to benefit from currently available immune oncology therapies. OncXerna\u2019s clinical trials currently combine bavituximab with KEYTRUDA\u00ae to test the hypothesis that relieving immunosuppression can enhance responses to checkpoint inhibitors. Bavituximab is an investigational agent that has not been licensed or approved anywhere globally, and it has not been demonstrated to be safe or effective for any use, including for the treatment of advanced gastric cancer.<\/p>\n<p align=\"justify\">KEYTRUDA\u00ae is a registered trademark of Merck Sharp &amp; Dohme Corp., a subsidiary of Merck &amp; Co., Inc., Kenilworth, NJ, USA.<\/p>\n<p align=\"justify\">\n        <strong>Investor and Media Contact:<\/strong>\n      <\/p>\n<p align=\"justify\">Ashley R. Robinson<br \/>LifeSci Partners, LLC<br \/>arr@lifesciadvisors.com\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MzA5NCMzOTQ5MTQ0IzUwMDA3MjgxMg==\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/9e24f0f0-444a-4c84-84e1-804491077114\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>WALTHAM, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) &#8212; OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-based biomarker platform to potentially predict patient responses to its first-in-class targeted oncology therapies, today announced the appointment of Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs. \u201cI am thrilled to reunite with Colleen and have her join our team given her deep expertise in oncology drug development,\u201d said Laura Benjamin, Ph.D., President and Chief Executive Officer at OncXerna Therapeutics. \u201cHer track record of success in developing and executing clinical development and regulatory strategies is impressive. This track record will be critical as we prepare to advance our navicixizumab and bavituximab programs towards registration trials using our &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;OncXerna Therapeutics Appoints Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-424476","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.4 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>OncXerna Therapeutics Appoints Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"OncXerna Therapeutics Appoints Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"WALTHAM, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) &#8212; OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-based biomarker platform to potentially predict patient responses to its first-in-class targeted oncology therapies, today announced the appointment of Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs. \u201cI am thrilled to reunite with Colleen and have her join our team given her deep expertise in oncology drug development,\u201d said Laura Benjamin, Ph.D., President and Chief Executive Officer at OncXerna Therapeutics. \u201cHer track record of success in developing and executing clinical development and regulatory strategies is impressive. This track record will be critical as we prepare to advance our navicixizumab and bavituximab programs towards registration trials using our &hellip; Continue reading &quot;OncXerna Therapeutics Appoints Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-01-29T12:08:24+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MzA5NCMzOTQ5MTQ0IzUwMDA3MjgxMg==\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"4 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"OncXerna Therapeutics Appoints Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs\",\"datePublished\":\"2021-01-29T12:08:24+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\\\/\"},\"wordCount\":836,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE0MzA5NCMzOTQ5MTQ0IzUwMDA3MjgxMg==\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\\\/\",\"name\":\"OncXerna Therapeutics Appoints Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE0MzA5NCMzOTQ5MTQ0IzUwMDA3MjgxMg==\",\"datePublished\":\"2021-01-29T12:08:24+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE0MzA5NCMzOTQ5MTQ0IzUwMDA3MjgxMg==\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODE0MzA5NCMzOTQ5MTQ0IzUwMDA3MjgxMg==\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"OncXerna Therapeutics Appoints Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"OncXerna Therapeutics Appoints Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\/","og_locale":"en_US","og_type":"article","og_title":"OncXerna Therapeutics Appoints Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs - Market Newsdesk","og_description":"WALTHAM, Mass., Jan. 29, 2021 (GLOBE NEWSWIRE) &#8212; OncXerna Therapeutics, Inc., a precision medicine company using an innovative RNA-based biomarker platform to potentially predict patient responses to its first-in-class targeted oncology therapies, today announced the appointment of Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs. \u201cI am thrilled to reunite with Colleen and have her join our team given her deep expertise in oncology drug development,\u201d said Laura Benjamin, Ph.D., President and Chief Executive Officer at OncXerna Therapeutics. \u201cHer track record of success in developing and executing clinical development and regulatory strategies is impressive. This track record will be critical as we prepare to advance our navicixizumab and bavituximab programs towards registration trials using our &hellip; Continue reading \"OncXerna Therapeutics Appoints Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\/","og_site_name":"Market Newsdesk","article_published_time":"2021-01-29T12:08:24+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MzA5NCMzOTQ5MTQ0IzUwMDA3MjgxMg==","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"4 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"OncXerna Therapeutics Appoints Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs","datePublished":"2021-01-29T12:08:24+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\/"},"wordCount":836,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MzA5NCMzOTQ5MTQ0IzUwMDA3MjgxMg==","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\/","name":"OncXerna Therapeutics Appoints Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MzA5NCMzOTQ5MTQ0IzUwMDA3MjgxMg==","datePublished":"2021-01-29T12:08:24+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MzA5NCMzOTQ5MTQ0IzUwMDA3MjgxMg==","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODE0MzA5NCMzOTQ5MTQ0IzUwMDA3MjgxMg=="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/oncxerna-therapeutics-appoints-colleen-mockbee-as-chief-development-officer-and-senior-vice-president-of-regulatory-affairs\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"OncXerna Therapeutics Appoints Colleen Mockbee as Chief Development Officer and Senior Vice President of Regulatory Affairs"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/424476","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=424476"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/424476\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=424476"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=424476"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=424476"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}